Chagas Disease: Chronic Chagas Cardiomyopathy

Area of Science:

• Infectious Diseases
• Cardiology
• Tropical Medicine

Background:

• Chagas disease (CD), caused by Trypanosoma cruzi, is a vector-borne infection endemic to South and Central America.
• Migration has increased the burden of CD in the United States and Europe.
• While the acute phase is often asymptomatic, the chronic phase can lead to significant organ damage, particularly cardiovascular and digestive complications.

Purpose of the Study:

• To review the pathophysiology and clinical manifestations of Chagas cardiomyopathy.
• To discuss current treatment strategies for Chagas disease and its chronic cardiac complications.
• To highlight the need for further research to improve clinical outcomes.

Main Methods:

• Literature review of studies on Chagas disease, Trypanosoma cruzi infection, and Chagas cardiomyopathy.
• Analysis of epidemiological data regarding the spread and impact of CD.
• Synthesis of information on current therapeutic approaches and ongoing research.

Main Results:

• Chagas cardiomyopathy is a leading cause of nonischemic cardiomyopathy in Latin America, affecting approximately 30% of infected individuals.
• Characteristic cardiac pathology includes diffuse myocarditis and focal fibrosis, predisposing to arrhythmias.
• Etiologic treatment is effective during the parasitic infection but lacks established efficacy in advanced chronic stages.

Conclusions:

• Chronic Chagas cardiomyopathy requires management similar to other nonischemic cardiomyopathies, but specific therapeutic advancements are needed.
• Further research is imperative to refine treatment protocols and improve the prognosis for patients with advanced Chagas disease.
• Ongoing studies aim to enhance clinical outcomes and develop more effective interventions for Chagas cardiomyopathy.